kidney cancer
Conditions
Interventions
Case series:neoantigen reactive tumor infiltrating lymphocytes
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years; 2. Histopathologically diagnosed as kidney cancer; 3. Availability of tumor tissue; 4. ECOG PS: 0-2; 5. Hematology Index including: Neutrophile granulocyte greater than 1.5×10^9/L, hemoglobin greater than 10g/dL and platelet greater than 100×10^9/L; 6. Life expectancy of greater than six months; 7. No active infection within two weeks; 8. Physician plans to use TIL treatment; 9. Consent to participate in clinical trials, Having full capacity for civil conduct.
Exclusion criteria
Exclusion criteria: 1. Analysis of gene sequencing data has not found enough neoantigens for subsequent treatment; 2. Patients with heart failure and severe pulmonary dysfunction; 3. Patients with autoimmune disease and immunosuppressive agents or hormone therapy; 4. Patients with serious uncontrolled infection, or other serious uncontrolled concomitant disease; 5. Patients with HIV and syphilis infection. 6. Patients whose genotype of Human leukocyte antigen (HLA) is homozygous or lacking alleles 7. Patients with Prior treatment using immuno-checkpoints inhibitor; 8. Patients with allergy to any interferon, interleukin 2; 9. Pregnancy or nursing females; 10. Patients with primary immunodeficiency or major organ autoimmune disease 11. T cell-associated lymphoma and leukemia patients; 12. Physicians believe that patients are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival;the rate of disease control; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactWeiren Huang
Shenzhen Second People's Hospital
Outcome results
None listed